Claims
- 1. A compound selected from the group, consisting of
- 2. A compound selected from the group consisting of
- 3. A compound selected from the group consisting of
- 4. A compound selected from the group consisting of
- 5. A compound selected from the group consisting of
- 6. A compound selected from the group consisting of
- 7. A compound selected from the group consisting of
- 8. A compound selected from the group consisting of
- 9. A compound selected from the group consisting of
- 10. A composition comprising
(a) an active agent; and (b) a compound selected from the group consisting of 75or salts thereof.
- 11. A composition comprising
(a) an active agent; and (b) a compound selected from the group consisting of 19A76CompoundnmXXXXVII004-ClXXXVIII30HXXXIX314-CH3XL312-FXLI312-CH3XLII303-CF3XLIII34HXLIV303-ClXLV303-FXLVI303-CH3XLVII002-CF3XLVIII12HXLIX322-FL303,4-OCH2O—LI302-COOHLII102-OHLIII302,6-dihydroxyLIV202-OHLV002,4-difluoroLVI202,6-dihydroxyLVII004-CF3LVIII303-NMe2LIX203-NMe2LX302,6-dimethylLXI302-NO2LXII302-CF3LXIII304-n-PrLXIV302-NH2LXV302-OCH3LXVI303-NO2LXVII303-NH2LXVIII202-NO2LXIX202-NH2LXX302-OCF3LXXI202-OCH3LXXII202-OCF3or salts thereof.
- 12. A composition comprising
(a) an active agent; and (b) a compound selected from the group consisting of 20B77CompoundnXLXXIII34-CF3LXXIV12-FLXXV14-CF3LXXVI33,4-dimethoxyLXXVII03-OCH3LXXVIII33-OCH3LXXIX32,6-difluoroLXXX34-CH3LXXXI14-OCH3LXXXII22-FLXXXIII02-FLXXXIV24-OCH3LXXXV02-OCH3LXXXVI22-OCH3LXXXVII04-CF3LXXXVIII33-FLXXXIX32-OCH3or salts thereof.
- 13. A composition comprising
(a) an active agent; and (b) a compound selected from the group consisting of 21C78CompoundnmXXC302-carboxycyclohexylXCI33cyclohexylXCII302-adamantylXCIII301-morpholinoor salts thereof.
- 14. A composition comprising
(a) an active agent; and (b) a compound selected from the group consisting of 22D79CompoundnXCIV0XCV3or salts thereof.
- 15. A composition comprising
(a) an active agent; and (b) a compound selected from the group consisting of 23E80CompoundXXCVIOHXCVII═Oor salts thereof.
- 16. A composition comprising
(a) an active agent; and (b) a compound selected from the group consisting of 24F81CompoundnXCVIII0XCIX2or salts thereof.
- 17. A composition comprising
(a) an active agent; and (b) a compound selected from the group consisting of 25G82CompoundnmXCXI602-OHCXII73HCXIII702-ICXIV702-BrCXV703-NO2CXVI703-N(CH3)2CXVII702-NO2CXVIII704-NO2CXIX902-OHor salts thereof.
- 18. A composition comprising
(a) an active agent; and (b) a compound selected from the group consisting of 26H83CompoundXCXX1-morpholinoCXXIO-t-ButylCXXIICH(CH2Ph)NC(O)O-t-BuCXXIII2-hydroxyphenylor salts thereof.
- 19. A composition as defined in claim 10, wherein said active agent is selected from the group consisting of a biologically active agent and a chemically active agent.
- 20. A composition as defined in claim 19, wherein said biologically active agent is selected from the group consisting of a peptide, a mucopoly-saccharide, a carbohydrate, a lipid, a pesticide, or any combination thereof.
- 21. A composition as defined in claim 20, wherein said biologically active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-II, insulin, heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, parathyroid hormone, desferrioxamine (DFO), or any combination thereof.
- 22. A composition as defined in claim 18, comprising parathyroid hormone and compound CXXIII or a salt thereof.
- 23. A dosage unit form comprising
(A) a composition as defined in claim 10; and (B)
(a) an excipient, (b) a diluent, (c) a disintegrant, (d) a lubricant, (e) a plasticizer, (f) a colorant, (g) a dosing vehicle, or (h) any combination thereof.
- 24. A dosage unit form according to claim 23, comprising a tablet, a capsule, or a liquid.
- 25. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 10.
- 26. A method for preparing a composition, said method comprising mixing:
(A) at least one biologically-active agent; (B) at least one compound as defined in claim 1; and (C) optionally a dosing vehicle
- 27. A method for administering an active agent to an animal in need of said agent, said method comprising administering to said animal a composition as defined in claim 10 wherein said composition is administered orally, intranasally, sublingually, intraduodenally, intramuscularly or subcutaneously.
- 28. A method for preparing a compound having the formula
- 29. A pharmacological composition comprising:
(A) at least one biologically-active agent; and (B) at least one carrier compound having the formula2—HO—Ar—CONR8—R7—COOHwherein Ar is a substituted or unsubstituted phenyl or naphthyl; R7 is selected from the group consisting of C4 to C20 alkyl, C4 to C20 alkenyl, phenyl, naphthyl, (C1 to C10 alkyl) phenyl, (C1 to C10 alkenyl) phenyl, (C1 to C10 alkyl) naphthyl, (C1 to C10 alkenyl) naphthyl, phenyl (C1 to C10 alkyl), phenyl (C1 to C10 alkenyl), naphthyl (C1 to C10 alkyl), and naphthyl (C1 to C10 alkenyl); R8 is selected from the group consisting of hydrogen, C1 to C4 alkyl, C1 to C4 alkenyl, C1 to C4 alkenyl, hydroxy, and C1 to C4 alkoxy; R8 is optionally substituted with C1 to C4 alkyl, C1 to C4 alkenyl, C1 to C4 alkoxy, —OH, —SH and —CO2R8 or any combination thereof; R9 is hydrogen, C1 to C4 alkyl or C1 to C4 alkenyl; R7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof; with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group; salts thereof.
Parent Case Info
[0001] This application is a Continuation-In-Part of application Ser. No. 08/414,654, filed Mar. 31, 1995 and Application Serial No. 60/003,111, filed Sept. 1, 1995.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60003111 |
Sep 1995 |
US |
|
60017902 |
Mar 1996 |
US |
Continuations (4)
|
Number |
Date |
Country |
Parent |
09499958 |
Feb 2000 |
US |
Child |
10038426 |
Oct 2001 |
US |
Parent |
09305506 |
May 1999 |
US |
Child |
09499958 |
Feb 2000 |
US |
Parent |
08798031 |
Feb 1997 |
US |
Child |
09305506 |
May 1999 |
US |
Parent |
PCT/US96/04580 |
Apr 1996 |
US |
Child |
08798031 |
Feb 1997 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08414654 |
Mar 1995 |
US |
Child |
PCT/US96/04580 |
Apr 1996 |
US |